UNSPSC 51162711: Erdosteine

This classification denotes a mucolytic agent with the molecular formula C8H11NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 76J0853EKA, chemically known as acetic acid, ((2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl)thio)- but more generally known as erdosteine, which bears US NIH Compound Identifier 65632. European Medicines Agency schedules Erdosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06595MIG.

UNSPSC 51162711 Erdosteine, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The two most recent opportunities show Seminole County, Florida soliciting naloxone and drug deactivation systems through an IFB, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issuing an RFP for generic multi-source pharmaceuticals and over-the-counter products — neither of which involves erdosteine, a mucolytic agent used in respiratory treatment. The code's nominal scope and the work actually being purchased diverge significantly, suggesting either a tagging error in the source data or minimal recent legitimate activity under this specific commodity classification. State and local procurement offices that do source erdosteine would typically do so as part of broader pharmaceutical or respiratory-care purchasing initiatives rather than as a standalone commodity line item.

The geographic spread of recent activity under this code is limited to Florida and Minnesota based on the two opportunities posted; however, the MMCAP procurement reaches multiple states through cooperative purchasing membership, including Oregon. No representative opportunities for erdosteine specifically are present in the recent solicitations, and no issuing body has solicited erdosteine as a discrete product within the past six months. Business development professionals evaluating this code should verify whether erdosteine demand exists within their target customer base through direct outreach rather than relying on recent tagged opportunities, as the current activity suggests the code sees little or no actual use for its intended pharmaceutical classification.